{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:28:06Z","timestamp":1790422086163,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008237","name":"Rottapharm Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008237","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.joca.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T10:44:27Z","timestamp":1568457867000},"page":"22-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial"],"prefix":"10.1016","volume":"28","author":[{"given":"L.C.","family":"Rovati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Blicharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vitalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bonazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Girolami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D'Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2019.09.002_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.berh.2011.11.008","article-title":"Osteoarthritis","volume":"25","author":"Hunter","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.joca.2019.09.002_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.berh.2014.01.004","article-title":"The epidemiology of osteoarthritis","volume":"28","author":"Johnson","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.joca.2019.09.002_bib3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.joca.2013.03.018","article-title":"The epidemiology and impact of pain in osteoarthritis","volume":"21","author":"Neogi","year":"2013","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2019.09.002_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","article-title":"OARSI guidelines for the non-surgical management of knee osteoarthritis","volume":"22","author":"McAlindon","year":"2014","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2019.09.002_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2014.05.014","article-title":"An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)","volume":"44","author":"Bruy\u00e8re","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.joca.2019.09.002_bib6","doi-asserted-by":"crossref","first-page":"iv99","DOI":"10.1093\/rheumatology\/kex522","article-title":"What is new in pain modification in osteoarthritis?","volume":"57","author":"Miller","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.joca.2019.09.002_bib7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.joca.2010.09.013","article-title":"OARSI-FDA initiative: defining the disease state of osteoarthritis","volume":"19","author":"Lane","year":"2011","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2019.09.002_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pharmthera.2017.03.009","article-title":"Imidazoline I(2) receptors: an update","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.joca.2019.09.002_bib9","first-page":"111","article-title":"Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain","volume":"4","author":"Ferrari","year":"2011","journal-title":"J\u00a0Pain Res"},{"issue":"5","key":"10.1016\/j.joca.2019.09.002_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FBP.0000000000000454","article-title":"Effects of imidazoline I2 receptor agonists on reserpine-induced hyperalgesia and depressive-like behavior in rats","volume":"30","author":"Siemian","year":"2019","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.joca.2019.09.002_bib11","first-page":"151","article-title":"CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats","volume":"5","author":"Meregalli","year":"2012","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.joca.2019.09.002_bib12","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1111\/bph.12728","article-title":"Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats","volume":"171","author":"Lanza","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joca.2019.09.002_bib13","first-page":"1033","article-title":"Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis","volume":"10","author":"Comi","year":"2017","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.joca.2019.09.002_bib14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/bph.13435","article-title":"Effects of the imidazoline I2 receptor agonist 2-BFI on the development of tolerance to and behavioural\/physical dependence on morphine in rats","volume":"173","author":"Thorn","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joca.2019.09.002_bib15","unstructured":"EU Clinical Trial Register. A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CR4056 Administered for 2 Weeks in Patients with Osteoarthritis of the Knee with Moderate to Severe Chronic Pain. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-001136-37\/results. (Accessed 16 January 2019)."},{"key":"10.1016\/j.joca.2019.09.002_bib16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee","volume":"29","author":"Altman","year":"1986","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.joca.2019.09.002_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/ard.16.4.494","article-title":"Radiological assessment of osteo-arthrosis","volume":"16","author":"Kellgren","year":"1957","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2019.09.002_bib18","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2019.09.002_bib19","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","article-title":"painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain","volume":"22","author":"Freynhagen","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.joca.2019.09.002_bib20","unstructured":"WHO Global Database on Body Mass Index. http:\/\/apps.who.int\/bmi\/index.jsp?introPage=intro_3.html. (Accessed 29 June 2017)."},{"key":"10.1016\/j.joca.2019.09.002_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12891-016-1286-2","article-title":"Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature","volume":"17","author":"Dell'Isola","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.joca.2019.09.002_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard.2004.022905","article-title":"Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement","volume":"64","author":"Tubach","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 39","key":"10.1016\/j.joca.2019.09.002_bib23","first-page":"S148","article-title":"The WOMAC knee and hip osteoarthritis indices: development, validation, globalization and influence on the development of the AUSCAN hand osteoarthritis indices","volume":"23","author":"Bellamy","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.joca.2019.09.002_bib24","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/acr.22538","article-title":"Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis","volume":"67","author":"Bellamy","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.joca.2019.09.002_bib25","doi-asserted-by":"crossref","first-page":"e007568","DOI":"10.1136\/bmjopen-2014-007568","article-title":"Body mass index and risk of knee osteoarthritis: systematic review and meta-analysis of prospective studies","volume":"5","author":"Zheng","year":"2015","journal-title":"BMJ Open"},{"issue":"Suppl 1","key":"10.1016\/j.joca.2019.09.002_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40266-019-00667-8","volume":"36","author":"Honvo","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.joca.2019.09.002_bib27","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.joca.2015.07.001","article-title":"Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement","volume":"23","author":"Reginster","year":"2015","journal-title":"Osteoarthr Cartil"},{"issue":"Suppl 10","key":"10.1016\/j.joca.2019.09.002_bib28","article-title":"Efficacy and safety of subcutaneous tanezumab for the treatment of osteoarthritis of the hip or knee (abstract)","volume":"70","author":"Schnitzer","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.joca.2019.09.002_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40266-017-0456-8","article-title":"Erratum to: can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis","volume":"34","author":"Bruy\u00e8re","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.joca.2019.09.002_bib30","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.joca.2016.07.017","article-title":"Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future","volume":"24","author":"Karsdal","year":"2016","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2019.09.002_bib31","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.joca.2017.08.009","article-title":"Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review","volume":"25","author":"Deveza","year":"2017","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2019.09.002_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/2049463713484296","article-title":"Obesity and pain","volume":"7","author":"McVinnie","year":"2013","journal-title":"Br J Pain"},{"key":"10.1016\/j.joca.2019.09.002_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12979-015-0049-5","article-title":"Characteristics of spinal microglia in aged and obese mice: potential contributions to impaired sensory behavior","volume":"12","author":"Lee","year":"2015","journal-title":"Immun Ageing"},{"key":"10.1016\/j.joca.2019.09.002_bib34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bcp.2018.01.032","article-title":"The imidazoline I(2) receptor agonist 2-BFI attenuates hypersensitivity and spinal neuroinflammation in a rat model of neuropathic pain","volume":"153","author":"Siemian","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.joca.2019.09.002_bib35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/bph.14161","article-title":"Mechanisms of imidazoline I(2) receptor agonist-induced antinociception in rats: involvement of monoaminergic neurotransmission","volume":"175","author":"Siemian","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.joca.2019.09.002_bib36","series-title":"Guideline on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis","year":"2010"},{"issue":"Suppl 107","key":"10.1016\/j.joca.2019.09.002_bib37","first-page":"68","article-title":"Pain sensitisation in osteoarthritis","volume":"35","author":"Arendt-Nielsen","year":"2017","journal-title":"Clin Exp Rheumatol"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458419312087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458419312087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:51:27Z","timestamp":1761018687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458419312087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1063458419312087"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2019.09.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736628903.793573715","asserted-by":"object"}]},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.","name":"copyright","label":"Copyright"}]}}